Trial
NCT03937999
Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Montefiore Medical Center
Collaborators
Merck Sharp & Dohme LLC
Condition
Clostridium Difficile
Intervention
Bezlotoxumab
Why stopped
Slow enrollment due to COVID19 , change in practice with standardized use of oral vancomycin prophylaxis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-09